SCHEMBL19009979

SCHEMBL19009979

Fc1cccc(P(c2ccccc2)c2ccccc2)c1-c1c(F)cccc1P(c1ccccc1)c1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
DRD1 P21728 2/20 0.41
ESR1 P03372 2/20 0.37
ESR2 Q92731 2/20 0.37
TOP1 P11387 2/20 0.35
TTR P02766 1/20 0.34
NFE2L2 Q16236 2/20 0.33
KDM4E B2RXH2 1/20 0.33
GAA P10253 1/20 0.33
PKM P14618 1/20 0.33
ACHE P22303 1/20 0.31
CASP3 P42574 1/20 0.31
SENP8 Q96LD8 1/20 0.31
SENP7 Q9BQF6 1/20 0.31
SENP6 Q9GZR1 1/20 0.31
PDK2 Q15119 1/20 0.31
NOS3 P29474 1/20 0.30
NOS2 P35228 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1768566 0.88 CYP3A4 (0.39) CYP3A4TDP1DRD1ESR1ESR2
SCHEMBL29005861 0.84 CYP3A4 (0.52) CYP3A4TDP1DRD1ESR1ESR2
SCHEMBL29593649 0.84 CYP3A4 (0.58) CYP3A4TDP1DRD1ESR1ESR2
SCHEMBL10797329 0.79 CYP3A4 (0.52) CYP3A4TDP1DRD1ESR1ESR2
SCHEMBL10700827 0.77 CYP3A4 (0.50) CYP3A4TDP1DRD1ESR1ESR2
SCHEMBL1768448 0.76 CYP3A4 (0.48) CYP3A4TDP1DRD1ESR1ESR2
SCHEMBL150139 0.75 TDP1 (0.69) CYP3A4TDP1DRD1ESR1ESR2
Acetic Acid SCHEMBL30620655 0.75 CES2 (0.41) CYP3A4TDP1DRD1ESR1ESR2
SCHEMBL301645 0.74 TDP1 (0.46) CYP3A4TDP1DRD1ESR1ESR2
SCHEMBL3934481 0.74 ESR1 (0.46) CYP3A4TDP1DRD1ESR1ESR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170173572-A1 CHIRAL LIGAND-BASED METAL-ORGANIC FRAMEWORKS FOR BROAD-SCOPE ASYMMETRIC CATALYSIS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2017-06-22 US disclosed
US-20170173572-A1 CHIRAL LIGAND-BASED METAL-ORGANIC FRAMEWORKS FOR BROAD-SCOPE ASYMMETRIC CATALYSIS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2017-06-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170173572-A1 CHIRAL LIGAND-BASED METAL-ORGANIC FRAMEWORKS FOR BROAD-SCOPE ASYMMETRIC CATALYSIS POF1B, FGFR1, COASY CYP3A4 1057/4885TDP1 4780/4885DRD1 2153/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.